RxDoctor Payments Data

Henry Ayiku, MD

Nephrology · North Charleston, SCNPI 1477509404

Payments from drug & device makers

$2,047in general payments, 2019–2025

Across 93 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$495
  • Aurinia Pharma U.S., Inc.$216
  • Mallinckrodt Hospital Products Inc.$194
  • Novartis$193
  • Travere Therapeutics, Inc.$170
  • AstraZeneca$106
  • plus $675 from 15 others

What the payments were for

  • Food & beverage$1,97596%
  • Education$724%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,047 in reported general payments places this provider in the 50th percentile of 180 nephrology providers in South Carolina.

See all nephrology providers in South Carolina

Medicare billing

Part B allowed, 2024
$253,561
Medicare patients
561
Services billed
3,216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin133$169,112
VelphoroSucroferric Oxyhydroxide24$74,031
VeltassaPatiromer Calcium Sorbitex41$34,945
FarxigaDapagliflozin Propanediol34$27,382
Sevelamer Carbonate38$8,446
Calcium Acetate28$2,295
Potassium Chloride23$1,669
Hydralazine Hcl47$909
Losartan Potassium75$786
Doxazosin Mesylate61$725
Metoprolol Succinate40$496
Lisinopril67$396
Amlodipine Besylate49$353
Chlorthalidone16$211
Midodrine Hcl12$177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$47$169,112133 claims
AstraZenecaFarxiga$106$27,38234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 180 nephrology providers in South Carolina.

Other nephrology in North Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →